Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-04-13
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresPCRX — Pacira Biosciences Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$24.51-8.13%Market cap951.11M
- Latest Close
- $24.51
- 30-Day Move
- -8.1%
- Market Cap
- $951M
- Shares Outstanding
- 40,490,000
- P/E Ratio
- 135.22
- P/B Ratio
- 1.61
NASDAQ:PCRXPharmaceuticals / PharmaceuticalsDelayed public snapshot
Pacira Biosciences Inc
A read-only Alphactor snapshot forPacira Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$24.51
30-Day Move
-8.1%
Market Cap
$951M
Shares Outstanding
40,490,000
P/E Ratio
135.22
P/B Ratio
1.61
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$24.51
-8.1%last 90 delayed daily bars
Market cap$951M
90D High
$27.16
90D Low
$18.80
Avg Volume
822,176
What stands out
Gross margin is running at 79.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 97.0%, useful for comparing PCRX against peers in Pharmaceuticals.
PCRX is down 8.1% over the last 30 trading days shown on this page.
Latest operating income is $33M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$44.35
Rule of 40
22.4%
Dark Pool Short %
42.3%
Fundamentals snapshot
Latest Close
$24.51
30-Day Move
-8.1%
Market Cap
$951M
Shares Outstanding
40,490,000
P/E Ratio
135.22
P/B Ratio
1.61
ROE
1.0%
ROA
56.0%
Gross Margin
79.4%
Operating Margin
99.0%
Net Margin
97.0%
Debt / Equity
0.54
Current Ratio
4.54
Latest Revenue
$726M
Financial statement snapshot
Revenue
$726M
Gross Profit
$577M
Operating Income
$33M
Net Income
$7M
Gross Margin
7939.0%
Net Margin
97.0%
Current Ratio
4.54
Debt / Equity
0.54
Valuation snapshot
Fair Value
$44.35
Upside / Downside
+81.0%
Signal
Undervalued
Implied Growth
-3.8%
DCF
$40.65
EPV
$9.12
EV/Rev
$83.29
Growth Assumption
2.9%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$137M
Valuation spread
Current Price
$24.51
Composite Fair Value
$44.35
DCF
$40.65
EPV
$9.12
EV/Rev
$83.29
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Quality snapshot
Altman Z
1.84
Grey
Piotroski
9
Strong (7-9)
Cash Conversion
21.61x
Rule of 40
22.4%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $667M | $71M | $16M | $115M |
| 2023-12-31 | $675M | $87M | $42M | $139M |
| 2024-12-31 | $701M | $98M | $-100M | $179M |
| 2025-12-31 | $726M | $33M | $7M | $137M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-06
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-01-26
Corticosteroids Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-10-27
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-10-23
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$3M
Buys
0
Sells
17
Buy Value
$0
Sell Value
$3M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-23 | Cross Shawn | M | 12,941 | $0.00 |
| 2026-04-23 | Cross Shawn | Sell | 12,941 | $25.16 |
| 2026-04-23 | Cross Shawn | M | 12,941 | $16.45 |
| 2026-04-22 | Cross Shawn | M | 1,500 | $0.00 |
| 2026-04-22 | Cross Shawn | Sell | 1,500 | $25.01 |
| 2026-04-22 | Cross Shawn | M | 1,500 | $16.45 |
| 2026-04-21 | Cross Shawn | M | 2,845 | $0.00 |
| 2026-04-21 | Cross Shawn | Sell | 2,845 | $25.01 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 2,617,657 | 0.06% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,283,992 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,087,897 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 928,800 | 0.02% | 2025-12-31 |
| IMPAX FUNDS SERIES TRUST I-Impax Small Cap Fund | 750,027 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 597,998 | 0.01% | 2025-12-31 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 569,157 | 0.01% | 2026-03-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 539,375 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-05-15
--
--
BlackRock
Filed 2024-05-10
$231M
--
Vanguard Group
Filed 2025-11-07
$134M
-3.9%
Renaissance Technologies
Filed 2025-08-13
$57M
+6.9%
D.E. Shaw
Filed 2026-02-17
$53M
+5.0%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.